The following  published technology appraisals guidance have been transferred to the static list.

Guidance is moved to the static list following consultation with consultees and commentators when it is clear that there is no new research available that would have any material effect on the current guidance. Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.

RefTitleDate IssuedReview decision
TA10 Asthma (children under 5) - inhaler devices  Aug 2000 Review decision
TA20 Motor neurone disease - riluzole Jan 2001 Review decision
TA23 Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) Mar 2016 Review decision
TA25 Pancreatic cancer - gemcitabine May 2001 Review decision
TA29 Leukaemia (lymphocytic) - fludarabine Sep 2001 Review decision
TA32 Multiple sclerosis - beta interferon and glatiramer acetate Jan 2002 Review decision
TA35 Arthritis (juvenile idiopathic) - etanercept Mar 2002 Review decision
TA38 Asthma (older children) - inhaler devices Mar 2002 Review decision
TA47 Acute coronary syndromes - glycoprotein IIb/IIIa inhibitors (review) Sep 2002 Review decision
TA48 Renal failure - home versus hospital haemodialysis Sep 2002 Review decision
TA49 Central venous catheters - ultrasound locating devices Sep 2002 Review decision
TA52 Myocardial infarction - thrombolysis Oct 2002 Review decision
TA53 Diabetes (types 1 and 2) - long acting insulin analogues Dec 2002 Review decision
TA55 Ovarian cancer - paclitaxel (review) Jan 2003 Review decision
TA59 Electroconvulsive therapy (ECT) Apr 2003 Review decision
TA60 Diabetes (types 1 and 2) - patient education models Apr 2003 Review decision
TA61 Colorectal cancer - capecitabine and tegafur uracil May 2003 Review decision
TA64 Human growth hormone (somatropin) in adults with growth hormone deficiency Aug 2003 Review decision
TA65 Non-Hodgkin's lymphoma - rituximab Sep 2003 Review decision
TA68 Macular degeneration (age-related) - photodynamic therapy Sep 2003 Review decision
TA69 Cervical cancer - cervical screening (review) Oct 2003 Review decision
TA70 Leukaemia (chronic myeloid) - imatinib Oct 2014 Review decision
TA73 Angina and myocardial infarction - myocardial perfusion scintigraphy Nov 2003 Review decision
TA74 Trauma - fluid replacement therapy Jan 2004 Review decision
TA75 Hepatitis C - pegylated interferons, ribavirin and alfa interferon Jan 2004 Review decision
TA77 Insomnia - newer hypnotic drugs Apr 2004 Review decision
TA78 Menstrual bleeding - fluid-filled thermal balloon and microwave endometrial ablation Apr 2004 Review decision
TA80 Acute coronary syndromes - clopidogrel Jul 2004 Review decision
TA81 Atopic dermatitis (eczema) - topical steroids Aug 2004 Review decision
TA82 Atopic dermatitis (eczema) - pimecrolimus and tacrolimus Aug 2004 Review decision
TA83 Hernia - laparoscopic surgery (review) Sep 2004 Review decision
TA85 Renal transplantation - immuno-suppressive regimens (adults) Sep 2004 Review decision
TA86 Gastrointestinal stromal tumours - imatinib Oct 2004 Review decision
TA92 HealOzone for the treatment of tooth decay (occlusal pit and fissure caries and root caries) Jul 2005 Review decision
TA94 Cardiovascular disease - statins Jan 2006 Review decision
TA96 Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alfa-2a Feb 2006 Review decision
TA98 Attention deficit hyperactivity disorder (ADHD) - methylphenidate, atomoxetine and dexamfetamine (review) Mar 2006 Review decision
TA100 Colon cancer (adjuvant) - capecitabine and oxaliplatin Apr 2006 Review decision
TA101 Prostate cancer (hormone-refractory) - docetaxel Jun 2006 Review decision
TA105 Colorectal cancer - laparoscopic surgery (review) Aug 2006 Review decision
TA106 Hepatitis C - peginterferon alfa and ribavirin Aug 2006 Review decision
TA112 Breast cancer (early) - hormonal treatments Nov 2006 Review decision
TA114 Drug misuse - methadone and buprenorphine Jan 2007 Review decision
TA115 Drug misuse - naltrexone Jan 2007 Review decision
TA116 Breast cancer - gemcitabine Jan 2007 Review decision
TA117 Hyperparathyroidism - cinacalcet Jan 2007 Review decision
TA118 Colorectal cancer (metastatic) - bevacizumab and cetuximab Jan 2007 Review decision
TA119 Leukaemia (lymphocytic) - fludarabine Feb 2007 Review decision
TA121 Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma Mar 2016 Review decision
TA123 Smoking cessation - varenicline Jul 2007 Review decision
TA124 Lung cancer (non-small-cell) - pemetrexed Aug 2007 Review decision
TA128 Haemorrhoids - stapled haemorrhoidopexy Sep 2007 Review decision
TA129 Multiple myeloma - bortezomib Oct 2007 Review decision
TA131 Asthma (in children) - corticosteroids Nov 2007 Review decision
TA134 Psoriasis - infliximab Jan 2008 Review decision
TA135 Mesothelioma - pemetrexed disodium Jan 2008 Review decision
TA136 Structural neuroimaging in first-episode psychosis Feb 2008 Review decision
TA137 Lymphoma (follicular non-Hodgkin's) - rituximab Feb 2008 Review decision
TA138 Asthma (in adults) - corticosteroids Mar 2008 Review decision
TA139 Sleep apnoea - continuous positive airway pressure (CPAP) Mar 2008 Review decision
TA143 Ankylosing spondylitis - adalimumab, etanercept and infliximab May 2008 Review decision
TA145 Head and neck cancer - cetuximab Jun 2008 Review decision
TA151 Diabetes - insulin pump therapy Jul 2008 Review decision
TA153 Hepatitis B - entecavir Aug 2008 Review decision
TA154 Hepatitis B - telbivudine Aug 2008 Review decision
TA155 Macular degeneration (age-related) - ranibizumab and pegaptanib Aug 2008 Review decision
TA156 Pregnancy (rhesus negative women) - routine anti-D (review) Aug 2008 Review decision
TA157 Venous thromboembolism - dabigatran Sep 2008 Review decision
TA158 Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir Sep 2008 Review decision
TA159 Pain (chronic neuropathic or ischaemic) - spinal cord stimulation Oct 2008 Review decision
TA164 Hyperuricaemia - febuxostat Dec 2008 Review decision
TA165 Organ preservation (renal) - machine perfusion and static storage Nov 2008 Review decision
TA166 Hearing impairment - cochlear implants Jan 2009 Review decision
TA168 Influenza - zanamivir, amantadine and oseltamivir (review) Sep 2008 Review decision
TA169 Renal cell carcinoma - sunitinib Mar 2009 Review decision
TA170 Venous thromboembolism - rivaroxaban Apr 2009 Review decision
TA171 Multiple myeloma - lenalidomide Jun 2009 Review decision
TA172 Head and neck cancer (squamous cell carcinoma) - cetuximab Jun 2009 Review decision
TA173 Hepatitis B - tenofovir disoproxil fumarate Jul 2009 Review decision
TA174 Rituximab for the first-line treatment of chronic lymphocytic leukaemia Jul 2009 Review decision
TA176 Colorectal cancer (first line) - cetuximab Aug 2009 Review decision
TA177 Eczema (chronic) - alitretinoin Aug 2009 Review decision
TA178 Renal cell carcinoma Aug 2009 Review decision
TA179 Gastrointestinal stromal tumours - sunitinib Sep 2009 Review decision
TA181 Pemetrexed for the first-line treatment of non-small-cell lung cancer: Dec 2014 Review decision
TA183 Cervical cancer (recurrent) - topotecan Oct 2009 Review decision
TA184 Lung cancer (small-cell) - topotecan Nov 2009 Review decision
TA185 Soft tissue sarcoma - trabectedin Feb 2010 Review decision
TA187 Crohn's disease - infliximab (review) and adalimumab (review of TA40) May 2010 Review decision
TA188 Human growth hormone (somatropin) for the treatment of growth failure in children (review) May 2010 Review decision
TA189 Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line) May 2010 Review decision
TA190 Lung cancer (non-small-cell) - pemetrexed (maintenance): Dec 2014 Review decision
TA191 Gastric cancer (advanced) - capecitabine Jul 2010 Review decision
TA192 Lung cancer (non-small-cell, first line) - gefitinib Dec 2014 Review decision
TA195 Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor Aug 2010 Review decision
TA197 Atrial fibrillation - dronedarone Aug 2010 Review decision
TA199 Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis Sep 2016 Review decision
TA200 Hepatitis C - peginterferon alfa and ribavirin Sep 2010 Review decision
TA208 Gastric cancer (HER2-positive metastatic) - trastuzumab Nov 2010 Review decision
TA209 Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib Nov 2010 Review decision
TA210 Vascular disease - clopidogrel and dipyridamole Dec 2010 Review decision
TA211 Constipation (women) - prucalopride Dec 2010 Review decision
TA212 Colorectal cancer (metastatic) - bevacizumab Dec 2010 Review decision
TA214 Breast cancer - bevacizumab (in combination with a taxane) Feb 2011 Review decision
TA215 Renal cell carcinoma (first line metastatic) - pazopanib Feb 2011 Review decision
TA216 Bendamustine for the first-line treatment of chronic lymphocytic leukaemia Feb 2011 Review decision
TA217 Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine Apr 2015 Review decision
TA218 Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia Mar 2011 Review decision
TA219 Everolimus for the second-line treatment of advanced renal cell carcinoma Apr 2011 Review decision
TA220 Golimumab for the treatment of psoriatic arthritis Sep 2016 Review decision
TA221 Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura Apr 2011 Review decision
TA223 Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease May 2011 Review decision
TA225 Rheumatoid arthritis (after the failure of previous anti-rheumatic drugs) - golimumab Jun 2011 Review decision
TA226 Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma Jun 2011 Review decision
TA227 Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy) Dec 2014 Review decision
TA228 Multiple myeloma (first line) - bortezomib and thalidomide Apr 2015 Review decision
TA229 Macular oedema (retinal vein occlusion) - dexamethasone Jan 2015 Review decision
TA230 Myocardial infarction (persistent ST-segment elevation) - bivalirudin Jul 2011 Review decision
TA232 Retigabine for the adjunctive treatment of partial onset seizures in epilepsy Jul 2011 Review decision
TA235 Osteosarcoma - mifamurtide Oct 2011 Review decision
TA236 Acute coronary syndromes - ticagrelor Oct 2011 Review decision
TA239 Breast cancer (metastatic) - fulvestrant Nov 2014 Review decision
TA242 Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy Mar 2015 Review decision
TA245 Venous thromboembolism - apixaban (hip and knee surgery) Mar 2015 Review decision
TA246 Pharmalgen for the treatment of bee and wasp venom allergy Feb 2012 Review decision
TA247 Rheumatoid arthritis - tocilizumab (rapid review TA198) Feb 2012 Review decision
TA249 Atrial fibrillation - dabigatran etexilate Mar 2012 Review decision
TA251 Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib Oct 2014 Review decision
TA256 Atrial fibrillation (stroke prevention) - rivaroxaban May 2012 Review decision
TA257 Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor) Aug 2015 Review decision
TA258 Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line) Dec 2014 Review decision
TA259 Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen Dec 2017 Review decision
TA260 Botulinum toxin type A for the prevention of headaches in adults with chronic migraine Jun 2015 Review decision
TA261 Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban Jun 2015 Review decision
TA263 Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer Aug 2015 Review decision
TA266 Mannitol dry powder for inhalation for treating cystic fibrosis Oct 2015 Review decision
TA268 Melanoma (stage III or IV) - ipilimumab Apr 2015 Review decision
TA269 Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib Jan 2015 Review decision
TA272 Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract Jan 2013 Review decision
TA274 Ranibizumab for treating diabetic macular oedema Apr 2015 Review decision
TA275 Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban Feb 2013 Review decision
TA276 Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis Oct 2015 Review decision
TA278 Omalizumab for treating severe persistent allergic asthma May 2016 Review decision
TA279 Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures Oct 2015 Review decision
TA284 Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer Jun 2016 Review decision
TA285 Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer Jun 2016 Review decision
TA287 Pulmonary embolism and recurrent venous thromboembolism - rivaroxaban Jun 2015 Review decision
TA293 Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (review of technology appraisal 205) Jul 2013 Review decision
TA294 Macular degeneration (wet age-related) - aflibercept Jul 2014 Review decision
TA297 Ocriplasmin for treating vitreomacular traction Feb 2017 Review decision
TA298 Ranibizumab for treating choroidal neovascularisation associated with pathological myopia Oct 2016 Review decision
TA300 Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people Nov 2013 Review decision
TA304 Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hip April 2017 Review decision
TA305 Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion Feb 2014 Review decision
TA307 Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy Mar 2014 Review decision

Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis

Mar 2014 Review decision
TA311 Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation April 2014 Review decision
TA314 Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure June 2014 Review decision
TA315 Canagliflozin in combination therapy for treating type 2 diabetes Oct 2017 Review decision
TA316 Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen Dec 2017 Review decision
TA317 Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes July 2014 Review decision
TA318 Lubiprostone for treating chronic idiopathic constipation July 2014 Review decision
TA321 Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma October 2014 Review decision
TA322 Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality Sep 2017 Review decision
TA340 Ustekinumab for treating active psoriatic arthritis Sep 2016 Review decision